At BXTA we are passionate about Prostate Cancer care
BXTA is one of the leading partners to hospitals and clinics worldwide, in providing brachytherapy to treat prostate cancer.
BXTA understands that offering prostate cancer patients brachytherapy depends on physicians having access to high-quality products delivered with expertise and reliability.
The organisation brings a new focus and unrivalled commitment to brachytherapy – and an established, world-class service.
BXTA believes all men and their families who are concerned they might be showing symptoms of prostate cancer, deserve access to the best possible support and care – from diagnosis to treatment.
With over 100 years’ combined experience, the BXTA team continues to bring new focus and unrivalled commitment to the diagnosis and treatment of prostate cancer.
LDR-B for prostate cancer involves the insertion of permanent radioactive ‘seeds’ directly into the prostate, which give off localised radiation over a number of months to treat the disease.
Changes made to the Medicare Benefits Schedule (MBS) in 2020 now encourage men to see both a urologist and a radiation oncologist to discuss their options prior to undergoing any active treatment for prostate cancer. Visit MBS Online for more information.
BXTA is the market leader for LDR-B in both Australia and New Zealand and is the leading international supplier of LDR-B outside of the Americas.
BXTA understands that offering prostate cancer patients brachytherapy relies on physicians having access to high quality products delivered with expertise and reliability. We bring a new focus and unrivalled commitment to brachytherapy – and an established, world-class service.
The PrecisionPoint™ transperineal (TP) access system enables free-hand prostate biopsy to be performed under local anaesthetic in a clinical setting. BXTA is proud to be the global distributor of PrecisionPoint™.
Utilising the TP pathway helps to minimise risk of infection by eliminating the need for the needle to pass through the rectum, as is required with transrectal (TR) biopsy.
Employing a single access needle, PrecisionPoint™ enables thorough sampling of all regions of the prostate including the anterior prostate, optimising cancer detection rates. The device allows for systematic template-style sampling without the need for a template or stepper and stabiliser unit.
The MBS now encourages TP biopsy as the standard of care and recommends patients are informed of the potential risks and provided with alternative methods to TR biopsy, ensuring they can make a suitable decision for their own unique circumstances. Visit MBS Online for more information.
BXTA is the global distributer of MRI PRO, the new, online self-learning tool for prostate MRI diagnostics, designed and developed by a team of specialist MRI radiologists and urologists.
MRI PRO is a subscription-based e-learning platform allowing healthcare professionals to test themselves on the highest quality histology-verified prostate MRI cases.
To learn more about BXTA, head to bxta.com/uk/healthcare-professionals.
BXTAccelyon Australia Pty Ltd
ABN: 55 165 390 241
Level 16, Tower 2 Darling Park,
201 Sussex Street,
Sydney, NSW 2000